Investigating serum exosomal annexin A2 in promoting aggressive TNBC in African American women

项目摘要 三阴性乳腺癌(TNBC)对非洲裔妇女的影响是非洲裔妇女的三倍 欧洲血统。患有TNBC的非裔美国妇女存活率低，死亡率高。 转移到远处的重要器官，如骨、肺和脑是TNBC最具破坏性的特征。它是 研究导致TNBC患者侵袭性疾病的分子机制至关重要(S)，以便 可以开发更好的治疗方案。新出现的证据表明，肿瘤来源的外切体 是肿瘤发生和组织特异性转移的介体，通过促进前- 转移的利基。膜联蛋白A2(Annexin A2，AnxA2)是一种常见的胞外蛋白，其水平升高 在TNBC患者血清和细胞系中。外体AnxA2(exo-AnxA2)在非洲的表达更高 美国人(AA)的TNBC患者比高加索人的TNBC患者的生存率低。我们最近的数据 提示exo-AnxA2在建立转移前的生态位中的作用，从而促进乳房 癌症转移。我们研究的长期目标是开发更好的治疗方案 侵袭性的TNBC对AA患者的影响不成比例。我们对拟议研究的假设是 Exo-AnxA2是TNBC转移侵袭性的决定因素，并与预后不良有关 再生障碍性贫血患者合并TNBC。这一假设的前提来源于文献(2，6-9，11)和我们发表的 数据表明，exo-AnxA2创造了一个转移前的利基环境，可能会推动侵袭性的TNBC转移。 我们将通过以下三个具体目标来解决这一假设：目标1：评估 不同种族人群中外源AnxA2的表达与疾病侵袭性的关系 人口。目的2：确定外源性AnxA2是否促进肿瘤侵袭性转移。目标3：确定 外源性AnxA2介导的转移生态位形成和侵袭性肿瘤的机制(S) TNBC。拟议研究的影响是可能鉴定出一种新的分泌性和外切体蛋白。 作为转移性肿瘤和靶间质之间远程通讯的功能调节器 微环境。此外，由于其胞外位置，分泌的AnxA2和伙伴蛋白代表 潜在的预见剂和治疗靶点。因此，我们期待这项研究将开辟令人振奋的新 TNBC患者转移检测、预后和治疗的临床转译途径。

Project Abstract Triple negative breast cancer (TNBC) affects women of African descent three times more than women of European descent. African American women with TNBC have poor survival and high mortality rates. Metastasis to distant vital organs such as bone, lung, and brain is the most devastating feature of TNBC. It is critical to investigate the molecular mechanism(s) that lead to aggressive disease in patients with TNBC so that improved therapeutic options can be developed. Emerging evidence suggests that tumor-derived exosomes are mediators of tumorigenesis and tissue-specific metastasis by contributing to the establishment of a pre- metastatic niche. Annexin A2 (AnxA2) is an often identified exosomal protein whose elevated levels are seen in TNBC patient sera and cell lines. Exosomal AnxA2 (exo-AnxA2) is more highly expressed in African American (AA) TNBC patients than in Caucasian TNBC patients resulting in reduced survival. Our recent data suggest a role for exo-AnxA2 in establishing a pre-metastatic niche which subsequently promotes breast cancer metastasis. The long-term goal of our research is to develop improved therapeutic options for aggressive TNBC that disproportionately affects AA patients. Our hypothesis for the proposed studies is that exo-AnxA2 is a determinant of the aggressiveness of TNBC metastasis and contributes to poor prognosis in AA patients with TNBC. The premise for this hypothesis stems from the literature (2, 6-9,11) and our published data indicating that exo-AnxA2 creates a pre-metastatic niche that may drive aggressive TNBC metastasis. We will address this hypothesis by the following three specific aims: Aim 1: Evaluate differences in the association of exo-AnxA2 expression with measures of disease aggressiveness among racially distinct populations. Aim 2: Determine whether exo-AnxA2 promotes aggressive TNBC metastasis. Aim 3: Determine the mechanism(s) that drives exo-AnxA2-mediated metastatic niche formation and aggressive tumors in TNBC. The impact of the proposed studies is the likely identification of a novel secreted and exosomal protein as a functional regulator of long-range communications between metastatic tumors and the target stromal microenvironment. Moreover, due to their extracellular location, secreted AnxA2 and partner proteins represent potential prognostic agents and therapeutic targets. Thus, we expect this research to open up exciting new avenues of clinical translation in metastasis detection, prognosis, and therapy for TNBC patients.